Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy

Study acronym: FLUORO
StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Jul 2025 to Jul 2027 Show 4 more changesShow less
    • Interventions: 4 Gy in 2 fractions (Radiation), Atezolizumab 1200 MG/40mL Intravenous Solution (Drug), Obinutuzumab 25 MG/1 ML Intravenous Solution (Drug) to 4 Gy in 2 fractions (Radiation), Atezolizumab 1200 MG/40mL Intravenous Solution (Drug), Obinutuzumab 25 MG/1 ML Intravenous Solution (Drug)
    • Eligibility criteria expanded, about 64 words
    • Collaborators revised (3)
    • Publications: details revised at 1 of 1 entry
  2. Re-verified, no change to tracked fieldsv13
  3. Collaborators: 4 to 3v12
  4. Collaborators: 5 to 4v11
  5. Primary completion date changed from estimate of Oct 30, 2023 to Apr 30, 2023
    • Study completion date: Jul 2024 to Jul 2025
    v10
Show 8 earlier versionsHide 8 earlier versions
  1. 2 versions Re-verified since Aug 30, 2023, no change to tracked fieldsv8-v9
  2. Primary completion date: Apr 30, 2023 to Oct 30, 2023v7
  3. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 4 to 3
    v6
  4. Site details revised at 1 of 4 sitesv5
  5. Site details revised at 1 of 4 sitesv4
  6. Site details revised at 1 of 4 sitesv3
  7. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 1, 2021 to Aug 17, 2021
    • Site details revised at 4 of 4 sites
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This single-arm phase II interventional study aims to assess disease response to, and toxicity of, a combination of obinutuzumab and atezolizumab, with or without radiotherapy, in treatment naive Follicular Lymphoma. The study will involve an induction phase and a maintenance phase for responding participants, for up to 24 months. Response to treatment will be monitored using medical imaging and clinical assessment.
Trial Details
NCT Number NCT04962126
Lead Sponsor Olivia Newton-John Cancer Research Institute
Collaborators: Hoffmann-La Roche, Austin Health, Ballarat Health Services
Conditions
(from sponsor)		 Follicular Lymphoma
Related terms Lymphoma, Follicular
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov